TW201233329A - Nutritional products including a novel fat system including monoglycerides - Google Patents

Abstract

Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.

Description

201233329 VI. Description of the Invention: TECHNICAL FIELD OF THE INVENTION The present invention relates to a nutritional product comprising pre-digested fat and to a method of using the nutritional product. More particularly, the present invention relates to infants, infants, and pediatrics comprising a fatty acid monoglyceride and/or fatty acid component. The product provides nutritional benefits including improved digestion, tolerance, and nutrient absorption. And reduce the incidence of necrotizing enterocolitis, abdominal pain and short bowel disease. CROSS-REFERENCE TO RELATED APPLICATIONS RELATED APPLICATIONS RELATED APPLICATIONS RELATED APPLICATIONS STATEMENT STATEMENT STATEMENT STATEMENT STATEMENT STATEMENT STATEMENT STATEMENT STATEMENT STATEMENT U.S. Provisional Application No. 6W42M76, the US Provisional Application No. 61/428,177, which was filed on December 29, and the US Provisional Application No. 61/428,185, which was filed on December 29, 2010 The disclosure of the 'intention' is incorporated herein by reference in its entirety. [Prior Art] Nutrient liquids and powders (including pediatric and pediatric formulas) containing targeted nutrients are well known and widely available, and some provide a single source of nutrients, while others provide supplemental sources. The material comprises a powder that can be reconstituted with water or other aqueous liquid, and a concentrated ready-to-drink nutrient liquid such as a milk or protein based emulsion. Liquids are especially useful when blended with selected nutrients. It is generally considered that breast milk is the best nutrition for newborn babies, but not every 161,215.doc 201233329 mothers can successfully breastfeed. Breastmilk substitutes (infant formulas) provide 70 whole nutrients and have been shown to meet normal growth and developmental nutritional needs of infants. Unfortunately, a small proportion of infant formula-fed newborns may experience gastrointestinal (GI) intolerance problems, including soft stools, flatulence, necrotizing enterocolitis, abdominal pain, and the like. The problem of GI intolerance can be attributed, at least in part, to incomplete digestion and absorption of nutrients by infants. To address this tolerance problem, some infant formulas exclude lactose as a component, while others replace hydrolyzed proteins with intact milk proteins to reduce the burden on the infant's digestive system. In addition, some formula silver newborn babies have a much lower rate of fat absorption than breast-fed babies. This difference in fat absorption rate decreases as the baby matures. It is speculated that newborn babies lack lipase and therefore cannot digest and absorb fat as well as breast-fed babies who receive lipase from breast milk. The digestive system of premature infants is less developed than the digestive system of full-term infants, which requires more nutrients (calories) than full-term infants to promote growth and development. Medium chain diglyceride S (MCT oil) is easy to digest and absorb and is included in preterm formula to improve formula fat, protein and calcium absorption. However, medium chain fatty acids in medium chain triglycerides are not used to re-synthesize triglycerides to form chylomicrons after digestion and absorption of MCT oil. Because many of the fat-soluble nutrients (such as carotenoids and vitamins A, d, Ε, and K) are encapsulated into chylomicrons before entering the systemic circulation, the benefits of mct oil for fat-soluble nutrient absorption (for growth) And development is also important) may be subject to more restrictions. 161215.doc 201233329 Despite attempts to address the GI problem and other issues mentioned above in the past, it is desirable to provide nutritional benefits similar to breast milk and also provide good tolerance and digestion of non-aqueous hydrophobic nutrients. And infants and pediatric formulations that absorb and reduce the incidence of conditions such as necrotizing enterocolitis, abdominal pain and short bowel disease. In addition, it would be beneficial if the formulations were free of stabilizers and in particular no carrageenan'. SUMMARY OF THE INVENTION The present invention relates to nutritional products, and in particular to infant formulas, which comprise pre-digested fats comprising a monoglyceride and/or fatty acid component comprising a fatty acid. These nutritional compositions can be advantageously used to improve the tolerance, digestion and absorption of nutrients (including water-insoluble/fat-soluble nutrients), and to reduce the incidence of diarrhea enterocolitis 'abdominal pain and short bowel disease. In certain embodiments, the fatty acid component can be in the form of a fatty acid or in the form of a calcium or magnesium salt of a fatty acid, thereby providing other benefits of other nutrients. One embodiment is a nutrient fat system comprising at least 1% by weight of 3 months old instant glycerin. At least 7 % of the fatty acid in the monoglyceride is in the Sn-Ι position. Another embodiment is an infant formula fat system comprising at least 1% wt% of 3 months old fat acid glycerol. At least 70% of the fatty acid in the monoglyceride S is in the Sn-Ι position. It has been found that nutrients (such as infants, toddlers, and pediatric formulas) comprising pre-digested fats (such as the monoglycerides and fatty acids as described herein) can reduce the overall burden of infants' digestive system to improve infant fat digestion. And absorb 161215.doc 201233329, containing water-insoluble / fat-soluble nutrient absorption. In particular, the absorption of pre-digested fat in the proximal part of the small intestine stimulates CCK secretion, which promotes pancreatic alpha-cell maturation and digestive enzyme secretion. In addition, GLP-1 and GLP-2 secretion are stimulated. This further promotes intestinal maturation. Surprisingly, the use of pre-digested fat and subsequent secretion of CCK and GLP-1 delays GI transport and stimulates pancreatic enzyme secretion to allow nutrient digestion and absorption to be more complete. A decrease in the amount of nutrients entering the infant's colon leads to a decrease in colonic fermentation, which is partly responsible for the problem of flatulence and soft stools. In addition, the use of pre-digested fat has been found to reduce the incidence of necrotizing enterocolitis, abdominal pain and/or short bowel disease. In addition, it has been found that the unsaturated fatty acid component of the pre-digested fat can react with the calcium or magnesium source and the resulting salt (4) provides good enthalpy for bio-p-removal or (d), and the material or magnesium salt is also surprising. (d) is milder than fatty acids that usually have a bitter taste and K is strongly irritated by the throat. In addition, it has been found that fat (tetra) salt or salt is surprisingly effective in stabilizing the nutritional emulsion. This is because you will not form a sinking substance that is difficult to disperse in the emulsion. Many insoluble strontium salts tend to be. Thus, the inclusion of a fatty salt or magnesium salt as part of the pre-digested fat in various embodiments may reduce the need for stabilizers such as keratin. [Embodiment] The nutrient described in the article includes pre-digested fat. In various embodiments, the product such as β Hai contains a fatty acid-containing pre-digested fat system comprising two hydrazine fatty acid components to contain two components. By reducing the burden on the child's digestive system, X infants or stable疋's bio-available products at the same time 16I215.doc 201233329 achieves a variety of benefits. The characteristics of the special and other features and changes in the presence of the military / T in the feed some of the details below are detailed below Description: The term "sterilization dad seal» Γ Μ 4* sleepy pack" and "sterilization|sterilization" can be used in this article, and unless otherwise ΒΒ τ . = 5, it means filling the nutrient liquid 5 |

(most commonly a metal can or i: #W, he is similarly packaged) and then subject the liquid-filled package to the necessary smashing halved ' & *,, 杈 杈 Μ Μ Μ Μ Μ Μ Μ Μ Μ Μ Μ Μ Μ Μ Common operations of the product. Unless otherwise stated, the term "aseptically packaged" as used herein means that the packaged product is manufactured independently of the sterilization step described above, wherein the technical base liquid and the package are separately sterilized prior to filling, and then killed or killed. The sterile processing conditions are combined to form a sterilized, aseptically packaged nutritional liquid product. The terms "fat" and "oil" as used herein, unless otherwise indicated, are used interchangeably to mean a plant or animal derived from or added to a lipid material. These terms also encompass synthetic lipid materials as long as the synthetic materials are suitable for oral administration to humans. The term "storage stable" as used herein, unless otherwise indicated, means that it is packaged and subsequently stored at 18_24t for at least 3 months (including from about 6 months to about 24 months, and also from about 12 months to (four) Commercially stable nutritional products after the month). The terms "nutritional formulation" or "nutraceutical" or plant nutritional composition as used herein are used interchangeably and, unless otherwise indicated, refer to liquids and solids (including semi-liquid and semi-solid) human milk fortifiers, Liquid and solid preterm formula, liquid and solid infant formula, liquid and solid phase II 161215.doc 201233329 Formula, liquid and solid pediatric formula and liquid and (4) infant formula. The solids can be a powder that can be reconstituted to form a nutrient liquid, all of which include one or more of fats, proteins, and carbohydrates and are suitable for oral administration to humans. The term "nutritional liquid" as used herein, unless otherwise indicated, means a nutrient in a ready-to-drink liquid form, a concentrated form, and a nutritional liquid prepared by reconstituting the nutritional powder described herein prior to use. Unless otherwise stated, the term "nutritional powder" as used in the context of $^pβ herein refers to a nutrient in a flowable or extractable form that can be reconstituted with water or another hydrazine 3 liquid prior to administration, and includes , mist drying and dry mixing / dry blending powder. The term "baby" means 12 premature baby means a person who is older or younger as used herein unless otherwise stated. An infant born before 36 weeks of gestation as used herein. Unless otherwise stated, persons over the age of three to three years of age, as used herein, the term "young child" means the term used by π people to be over the age of twelve. Unless otherwise stated, the term "pre-digested lipids" as used in this instruction refers to mono-acids containing fatty acids (IV). Unless otherwise stated, it is as follows (4) (4). Refers to the term "infant formula" used by the infant as the primary source of liquid and solid nutritional supplements unless otherwise stated.

J refers to liquid and solid nutrients suitable for preterm infants to be used as the main preterm formula. i612l5.doc 201233329 The term "human milk fortifier" as used herein, unless otherwise stated, is a palatable and breast or premature formula or infant formula. Liquid and solid nutritional supplements for preterm or full-term infants. ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” ” One is a glyceride covalently bonded to a fatty acid chain of a glycerol molecule. ^非其他儿明' $ The term "fatty acid component" as used herein is derived from free fatty acids in which the total amount of meat ugly acid, palmitic acid and stearic acid is less than that of the free (at θ) source. A fatty acid salt (such as a fatty acid calcium or magnesium salt). The term "liposoluble nutrient" as used herein, unless otherwise indicated, refers to water-insoluble nutrients such as oil-soluble (fat-soluble) vitamins (eg, vitamins A, D, £ and strontium), carotenoids (eg, lutein). , β-moon radish, ruthenium, etc.), glycolipids (neurolipids), sterols and phytochemicals. Nothing is explicitly disclosed, and the numerical ranges used herein are intended to include each of the numerical and numerical sub-sets within the range. n. The numerical ranges should be construed as supporting the claim of any value or subset of values within the range. . For example, the disclosures 2 to 10 should be understood to support ranges of 2 to 8, 3 to 7, 5 to 6, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, and the like. All singular features or limitations of the present invention are intended to include the corresponding singular features or limitations, and vice versa, unless otherwise stated or indicated to the contrary. 161215.doc 201233329 All methods or combinations of process steps as used herein may be performed in any order, unless otherwise stated or implicitly stated to the contrary. ~ Each embodiment of the nutritional product of the present invention may also be substantially free of any components or features present or selected as described herein, with the proviso that the remaining nutritional products should still contain all of the desired ingredients as described herein or feature. In this context, and unless otherwise stated, the term "substantially absent" means that the selected nutrient contains less than a functional amount of the component, as opposed to 1% by weight (including less than 0.5% by weight, including less than 〇. The % by weight and also the % by weight of the component present or selected as appropriate. The nutraceuticals and methods can comprise, consist of, or consist essentially of, the product elements described herein, as well as any other or optionally existing elements described herein or otherwise applicable to the use of the nutraceutical and method. Product Form The pre-digested fat-containing nutrient of the present invention and related methods can be formulated and executed in any known or otherwise suitable oral product form. Any solid, semi-solid, liquid, semi-liquid or powder form, including combinations or variations thereof, is used herein with the proviso that such forms permit safe and effective oral delivery to an individual as also defined herein. Each component. The nutritional product of the present invention comprises pre-digested fat as described herein. Such products may optionally comprise a combination of a fatty acid containing monoglyceride or fatty acid component with other fat sources as described below. Such products may comprise any of the product forms including the ingredients described herein and which are safe and effective for oral administration. The nutraceuticals may be formulated to contain only the ingredients of 161215.doc -10· 201233329 as described herein, or may be modified as appropriate to form a plurality of different product forms. The nutritional product of the present invention is preferably formulated in the form of a dietary product, which is defined herein as a product form comprising at least one of fat, protein and carbohydrate, and preferably also vitamins, minerals or combinations thereof. Examples of the components of the invention. In various embodiments, the product will include a combination of pre-digested fat with protein, carbohydrates, vitamins and minerals to produce a nutritional product. These nutrients may be formulated with sufficient types and amounts of nutrients to provide a single, primary or supplemental source of nutrition, or to provide an individual dedicated to a particular disease or condition or a nutritional product having a targeted nutritional benefit. Specific non-limiting examples of product forms for use with pre-digested fats as disclosed herein include liquid and powdered human milk fortifiers, liquid and powdered premature silk, liquid and powdered infant formulas, Liquid and powdered ingredients and semi-element formulas, liquid and (iv) pediatric formulas, and liquid and powdered infant formulas. Nutrient Liquids Nutrient liquids contain concentrated and ready-to-eat nutrient liquids. These nutrient liquids are most commonly formulated as suspensions or emulsions. Suitable nutritional emulsions can be aqueous emulsions containing proteins, fats and carbohydrates. These lotions are around! It is typically a flowable, drinkable liquid at about 25 ° C and is typically in the form of an oil-in-water, water-in-oil or composite aqueous emulsion, although the emulsions are most generally water with a continuous aqueous phase and a discontinuous oil phase. In the form of an oil-in-water emulsion. 1612l5.doc -11 · 201233329 Nutritional emulsions are stable to storage and generally stable to storage. The nutritional emulsions generally comprise up to about 95% by weight water, including from about 50% to about 95% by weight, and also from about 6% to about 90% by weight, and also about 7 Å, by weight of the nutritional emulsion. From % by weight to about 88% by weight of water. The nutritional emulsions can have a variety of product densities, but most typically have a regimen of greater than about 丨〇3 g/ml, including greater than about 丨〇4 g/mi, including greater than about 丨〇55 g/ml, including about 1.06 g/ Ml to about 1.12 g/ml, and also includes from about 1.085 g/ml to about 1.10 g/ml. The nutritional emulsion can have a caloric density tailored to meet the nutritional needs of the end user's. However, in most cases the emulsions typically comprise at least 19 kcal/fl oz (660 kcal/liter), more typically about 2 〇. Kcai/fi 〇z (675_ 680 kcal / liter) to about 25 kcal / fl 〇 z (820 kcal / liter), and even more generally about 20 kcal / fl 〇 z (675-680 kcal / liter) to Approximately 24 kcal/fl oz (800-810 kcal/litre). In general, 22_24 kcal/fl 〇z (74〇_ 810 kcal/litre) formula is more commonly used in preterm or low birth weight infants, and 20-21 kcal/fl OZ (675-680 to 700 kcal/ Liters) formulas are more commonly used in term infants. In certain embodiments, the emulsion can have a caloric density of from about 1 kilocalyptus per liter to about 660 kilocalories per liter, including from about 15 kilocalories per liter to about 500 kilocalories per liter. The nutritional emulsion can have a pH in the range of from about 3.5 to about 8, but most advantageously in the range of from about 4.5 to about 7.5' including from about 5.5 to about 7.3, including from about 6.2 to about 7.2. Although the amount of nutrient emulsion can vary depending on a variety of variables, typical dosages are typically at least about 2 mL, or even at least about 5 mL, or even up to 161215.doc 12 201233329 includes from about 2 mL to about 300 mL, and includes About ίο mL·to about

Less than 10 mL' or even at least about 25 llU, including about 4 mL to about 250 mL 240 mL. As noted above, the nutritional product may also be in a semi-liquid form, including such forms in which the properties (such as flow characteristics) are intermediate (between the liquid and the solid). Examples of non-volatile semi-liquids include viscous shakes and liquid gels. The nutritional solid can be in any solid form, but is generally in the form of a flowable or substantially flowable particulate composition, or at least a particulate composition. Particularly suitable nutritional solid product forms include spray dried, coalesced or dry blended powder compositions. The compositions can be readily prepared or measured with a spoon or similar device, wherein the compositions can be readily reconstituted by a prospective user with a suitable aqueous liquid (typically water) to form a nutritional formulation. For immediate oral or enteral use. In this context, "immediate" use generally means that it is preferably within about 48 hours of recovery, most typically within about 24 hours. The nutritional powder can be reconstituted with water prior to use to a caloric density tailored to meet the end user's nutritional needs, but in most cases the powder is reconstituted with water to form at least 19 kcal/fl oz (660 kcal/liter) ), more generally about 20 kcal/fl oz (675-680 kcal / liter) to about 25 kcal / fl oz (820 kcal / liter), and even more generally about 20 kcal / fl oz (675-680 thousand Card/L) to a composition of approximately 24 kcal/fl oz (800-810 kcal/liter). In general, 22-24 kcal/fl oz (740-810 kcal/litre) formula is more commonly used in preterm or low birth weight infants, and 20-21 kcal/fl 161215.doc -13- 201233329 M675-680 Formulas up to 700 kcal/litre are more commonly used for term infants. In some embodiments, the reconstituted powder can have a caloric density of from about 5 kcal/liter to about 66 kcal, including from about 100 kcal/liter to about 5 kcal/liter. As noted above, the nutritional product may also be in a semi-solid form, including such forms as properties (such as stiffness) in the intermediate state (between the solid and the liquid). Some semi-solid examples include puddings, gelatin and creams. Pre-digested fat system Α. Monoglyceride containing glycerin in certain embodiments. In certain embodiments, the nutritional product of the present invention comprises a fatty acid-containing monoglyceride, alone or in combination with a fatty acid component as described below, also referred to as Monothiol glycerol. Monoglyceride is a normal metabolite formed in the body when triglyceride and diglyceride are decomposed. As stated, the fatty acid-containing monoglyceride may be included in the nutrient in combination with a fatty acid component such as a fatty acid and/or a fatty acid salt as described below, or may be included in the absence of the fatty acid component. In the nutrition. A fatty acid-containing monoglyceride suitable for use in a nutritional product may comprise a fatty acid having a chain length of 4 to 22 carbon atoms, including a fatty acid having a chain length of 14 to 20 carbon atoms, and including palmitic acid (16 carbon atom). Particularly preferred is a monoglyceride wherein at least 70% of the fatty acids in the monoglyceride are at the Sn-1 position (also referred to as the alpha position), including at least about 70% palmitic acid residues at the Sn-1 position. The monopalmitate 'includes at least about 80% at the Sn-1 position and includes from about 85% to about 100% at the Sn-1 position. Moreover, in certain embodiments, the monoglycerides comprising 161215.doc • 14 to 201233329 in the nutritional products described herein may include trace amounts of diglycerides, free glycerol, and/or free fatty acids. As used herein, the term "trace" means no more than 1 〇 Wt%, but more typically less than 7.5 wt%. In a particular embodiment, the monoglyceride in the nutrient (and, as the case may be, the fatty acid component as discussed below) is provided to the product, either partially or completely via the use of hydrolysate or hydrolyzed animal fat. Lard, tallow and other animal-based products can be added to the nutrient and hydrolyzed by pancreatic lipase to monoglycerides and fatty acids. Alternatively, lard or tallow can be hydrolyzed and incorporated into the nutrient to produce a single Acid glycerides and fatty acids, which can be incorporated into nutrients. Lard, tallow or hydrolyzed lard or tallow may provide some or all of the monoglycerides and/or fatty acids in the nutrient. In another embodiment, the monoglyceride in the nutritional product is partially or completely derived from an oil such as vegetable oil, aquatic animal oil, fish oil, algae oil, fungal oil, resin, and combinations thereof. For example, suitable vegetable oils include eucalyptus oil, canola oil, corn oil, palm oil, soybean oil, and combinations thereof. The fatty acid-containing monoglyceride is present in the nutritional product + in an amount of 10% by weight of the fat component contained in the nutrient, including at least about 15 weights in the fat component of the nutritional product. %, including at least about 2 G weight% of the monthly fat group included in the nutrient, including 12% by weight to 45% by weight, including 15% by weight and including about 1%, based on the fat component contained in the nutrient. % by weight, including about 15% by weight. /. Including about 20% by weight, package: about 25% by weight, including about 3% by weight and further including (iv) by weight. Or even a weight of 1%, or even about 5 inches. /. Or even about 161215.doc -15· 201233329 wt%, or even about 70 wt%, or even about 80 wt%, or even about 90 wt%, or even about 1 wt%. In a particular embodiment, 'when the nutritional product is a nutritional powder comprising about 28% (by weight of the nutritional powder) of the fat component, the fatty acid-containing monoglyceride is about 1% by weight (by weight of the fat component) The content of the compound is present, or about 2.8 grams of fatty acid monoglyceride per 100 grams of nutritional powder. In another specific embodiment, when the nutritional product is a ready-to-feed nutritional liquid comprising about 3.67% (by weight of the ready-to-feed nutritional liquid) fat component, the fatty acid-containing monoglyceride is about 1% The content (based on the weight of the fat component) is present or 'about 367 grams per 100 grams of ready-to-feed nutritional liquid, pre-acid glycerin containing tartaric acid. In another specific embodiment, when the nutritional product is a concentrated nutritional liquid comprising about 734% (by weight of the concentrated nutritional liquid) of the fat component, the fatty acid-containing monoglyceride is about 10% ( The content of the weight of the fat component is present or 'about 734 grams per 100 grams of concentrated nutrient liquid, which contains the early acid glycerin of the fatty acid. In addition to providing the various benefits listed above, it has also been found that monoglycerides containing fatty acids have antiviral and/or antibacterial activity in the nutritional product. In particular, it has been found that the presence of fatty acid monoglycerides in the nutritional product kills the pathogen and/or slows its replication. B. Fatty acid component In addition to or in place of the above-mentioned monoglyceride containing fatty acid, the nutritional product of the present invention may comprise a fatty acid component containing a fatty acid as part of a pre-digested fat system. . Fatty acids are in the body when they are decomposed in I612l5.doc -16- 201233329 fats (triglycerides, diglycerides, cholesterol esters and certain phospholipids)! The normal metabolite formed by the page. The f-fatty acid component is independent and distinct from the fatty acid-containing monoglyceride discussed above. Any fatty acid that is beneficial in the nutritional product can be included in the nutritional product as part of the pre-digested fat system. In one embodiment, the fatty acid is an unsaturated free fatty acid. In certain embodiments comprising an unsaturated free fatty acid, the total amount of unsaturated free fatty acids having a chain length of more than 14 carbon atoms is less than 15 wt%. Exemplary fatty acids suitable for inclusion in the nutrients described herein include, but are not limited to, arachidonic acid, linoleic acid, docosalic acid, stearidonic acid, oleic acid, twenty Carboxenoic acid, mead acid, erucic acid, nervonic acid, and mixtures and combinations thereof. Particularly preferred fatty acids include arachidonic acid, linoleic acid, linoleic acid, docosahexaenoic acid and oleic acid. The fatty acid component contained in the pre-digested fat system includes those fatty acid components derived from oils such as vegetable oils, aquatic animal oils, fish oils, seaweed oils, fungal oils, animal fats, animal fat isolates, and combinations thereof. For example, suitable vegetable oils include olive oil, canola oil, corn oil, soybean oil, and combinations thereof. In one embodiment, 'when animal fat is used, the fatty acid is obtained by enzymatic hydrolysis of lard or tallow, and the content of palmitic acid and stearic acid in the resulting fatty acid mixture is reduced to less than 20% of the total fatty acid. Includes less than 2% of total fatty acids. In another embodiment, at least some of the fatty acids are derived from soybean oil or a resin. Once derived from the oil source, the fatty acid is substantially free of monoglycerides, diglycerides, and triglycerides. The fatty acid will typically be derived from a source oil containing less than about 20% by weight palmitic acid and /161215.doc 17 201233329 or stearic acid and/or myristic acid. In certain embodiments, the fatty acid will be derived from containing less than about 15% by weight, including less than about 10% by weight, including less than about 5% by weight, and including less than 2% (in terms of Weight leaf) The source oil of citric acid and / or stearic acid and / or meat and vegetable acid. In a particular embodiment, the fatty acid is derived from less than about 20% by weight 'comprising from about 10% by weight to about 15% by weight of palmitic acid and/or stearic acid and/or Or the source of myristic acid. In another particular embodiment the 'nutrient comprises plucking acid in an amount of less than about 10% by weight based on total fatty acids. In certain embodiments the 'nutrient may comprise a fatty acid in the form of a salt; i.e., the fatty acid may be added to the nutrient as a fatty acid salt. In a suitable embodiment, the fatty acid is added to the nutritional product in the form of a fatty acid calcium salt, a fatty acid magnesium salt, or a combination thereof. Fatty acid salts can be prepared by those skilled in the art based on the disclosure herein. In a suitable process, an emulsion comprising a c10_C24 fatty acid calcium salt can be prepared by first preparing a fatty acid salt by using a right stem starting calcium source mixed with at least one c]Q _ C 2 4 fatty acid source. More specifically, in the method, the starting source comprising the C 〇-C24 fatty acid in the form of a triglyceride blend or in a free form can be contacted by calcium hydroxide and/or calcium carbonate or calcium phosphate. And formed. In another method, it is triglyceride-oxime. The Citr C24 fatty acid in free form or in free form can be obtained by hydration with a mouth value of 6 to about 7.5 (: 3 (: 12 or (: ^ (eight (: 〇) 2). In an inert atmosphere, for example under N2 or argon. In any other example, 'any of the disclosed methods can be carried out under ambient conditions 1612l5.d -18· 201233329 (eg, where the reaction is not carried out under a low oxygen atmosphere) Sources containing C1Q-C24 fatty acids and calcium sources can be mixed by any means known to this. "Mixing" does not mean implying that a particular fruit 'such as any component dissolves to a certain extent or forms a specific group of eight° such as a homogeneous mixture) 'However, such mixtures can be produced and (the two components of the wood can be dissolved by mixing. The mixing can be vigorous and can be manually or smashed by mechanical means such as (but not limited to) static mixers, magnetic stirrers , π decanter, rotator or rotating device). Mixing can be carried out by forcing the gas through the mixture or by bubbling the gas through the mixture or by sonication. The c1〇-c24 fatty acid source can be mixed with the feed source. to Minutes. Mixing can also be performed at least 1, 5, 15, 20, 25, 30, 35, w 40 , 45 , 5 〇, 55, 60, 65, 70, 75, 8 〇, 85, 9 〇, 95 or 1 〇〇 minutes, any of which may form an upper or lower end if appropriate. Mixing can be carried out at various temperatures, but the method generally occurs at elevated temperatures. The exact high temperature can depend on C gram G_C24 fatty acid or calcium Specific starting sources and amounts thereof. Suitable temperatures at which the disclosed mixing can be carried out include, but are not limited to, from about 4 ° C to about 1 Torr (TC, about 1 Torr. (: to about i 〇〇 ° c, From about 15 ° C to about 100 ° C, or from about 20 ° C to about 70 ° C. Sources containing C1G-C24 fatty acids or calcium may also be heated prior to mixing. This preheating step can be any of those described herein. The temperature or temperature range is carried out. In certain embodiments, the mixing of the C10-C24 fatty acid with calcium can be carried out under reduced pressure. Suitable pressures are less than or equal to about 1 Torr or less than or equal to about 0.1 Torr. In a preferred embodiment, the CI0-C24 fatty acid calcium salt is separated from (:1()-〇:24 unsaturated fat by adding 161215.doc 19 201233329 Acid and calcium source (such as Ca (〇H) 2, Shu 2,

CaC〇3, calcium citrate or a mixture of such salts) is prepared to form an oil blend. More specifically, the fatty acid is dissolved in a warm aqueous solution (e.g., having a temperature of from about 40 C to about 80 C). The pH of the solution can be adjusted to generally about 1 〇 _kp· using K 〇 H4Na〇H. The fatty acid and hydrazine are then added to the dissolved fatty acid-containing solution to allow for a complete reaction between the fatty acid and the (tetra). The mixture is then homogenized to form an oil cocktail. In another ideal implementation list, a mixture of fatty acid salts (including fish oil, sea oil, fungal oil, and soybean oil (Q1, (1) fatty acids) is prepared as part of the pre-digested fat system. Fish oil, algae oil, The fungal oil and the soybean oil are mixed together and hydrolyzed by potassium hydroxide under a nitrogen blanket. Then, about a source (such as a gasification mother) is added to the mixture to react with the fatty acid to produce an insoluble fatty acid calcium salt. The salt can be separated by filtration and washed with water and then dried under vacuum. It has been surprisingly found that although fatty acid salts (such as fatty acid calcium salts) are not/in combination with nutrients, they do not settle in solution. Forming a sediment layer that is difficult to redisperse. Thus, the use of fatty acid calcium salts and/or fatty acid magnesium salts provides better calcium/magnesium delivery and, in various embodiments, eliminates other stabilizers (such as horn gum The need to make the product substantially or completely "carrageenan". Therefore, compared to products that use calcium phosphate or calcium carbonate as a source of calcium. The fatty acid salt improves the bioavailability of calcium and/or magnesium and fatty acids. Furthermore, it has been found that the use of fatty acid salts in the nutritional products of the present invention provides 161215.doc -20-201233329 availability of fatty acids such as arachidonic acid (ara) And its analogues, which are shown to enhance the growth of infants. The use of pre-digested fat also provides milky nutritional supplements with improved product stability and long shelf life. Nutritional products usually include fat components included in the nutritional supplements. At least about 10% by weight of the fatty acid or fatty acid salt, including at least about 5% by weight, including at least about 2% by weight, including about 10% by weight to about 8% by weight of the nutritional component. 60% by weight, including about 15% to about 40% by weight, and including about 15% to about 35% by weight, including about 1% by weight, including about 15% by weight, including about 20% by weight, including about 25 weight %, including about 30% by weight, including about 35% by weight and further including about 4% by weight A, or even about 50% by weight, or even about 6% by weight, or even about 7% by weight, or even about 80 weight %, or even about 9% by weight, or even about 100% by weight. In certain embodiments, the #养品 comprises a mixture of a fatty acid component and a fatty acid containing glycerol (tetra). In these embodiments, the nutritional product contains two The compound comprising 'at least 1% by weight (by weight) of the fat component contained in the alpha comprises at least about Η weight/〇, including at least about 20 weights, based on the fat component contained in the nutritional product. %, including from about 10% by weight to about 40% by weight, including from about 20% by weight to about 65% by weight, including from about 25% by weight to about 5% by weight, from about 15% by weight to about 3% by weight And comprising from about 5% by weight to about 25 mils/inch, including about 10% by weight, including about 15% by weight, including about 20 mils, including about 25% by weight, including about 3% by weight, including about 35 wt%, η *ζ*. and further comprising about 40% by weight or even about 5% by weight, or even about 6% by weight, or even about 70% by weight, or even about 80% 161215.doc 21 201233329 % Or even about 90% by weight or even about 1% by weight. In other embodiments, the nutritional product comprises at least 0.2% by weight, including at least 1% by weight, including at least 2% by weight, and including at least 5%, by total dry matter in the nutritional product. A fatty acid component (by weight), a fatty acid-containing monoglyceride, or a combination thereof. Macronutrient Although the total concentration or amount of fat, protein and carbohydrate can be determined by product type (ie 'human milk fortifier, infant formula, etc.), product form (ie nutrient solids, powder, ready-to-feed liquid or concentrated) The type of liquid) and the intended user's target dietary requirements vary, but such concentrations or amounts are most generally within one of the following specific ranges, including any other fat, protein, and/or carbohydrate component as described herein. For liquid preterm and term infant formulas, the carbohydrate concentration is most generally from about 40%, including from about 7% to about 30%, including about 1% by weight of the preterm or term infant formula. . To a range of about 25%, the fat concentration (including pre-digested fat and any other fat source) is generally from about 1% to about 3%, including about 2% to about the weight of the preterm or term infant formula. 15% and including from about 3% to about 丨〇%; and the protein concentration is most preferably from about 5% to about 30%, including about 1% to about the weight of the preterm or term infant formula. 15% and include from about 2% to about 1%. For liquid human milk fortifier products, the carbohydrate concentration is most typically from about 1% to about 75% by weight of the human milk fortifier, including the bonus. To about 50%, including about 2G% to about (4), the ratio of the weight of the human milk to 161215.doc -22-201233329, the fat concentration (including pre-digested fat and any other fat source) is most generally about 10 % to about 40%, including from about 15% to about 37%, and including from about 18% to about 30%; and the protein concentration is most generally from about 5% to about 40% by weight of the human milk fortifier, It includes from about 1% to about 30% and includes from about 15% to about 25%. In addition to or as an alternative to the percentage of total calories in the nutritional products listed in the following table, the amount or amount of carbohydrate, fat and/or protein in the liquid nutritional product is also characterized. The macronutrients used in the liquid nutritional products of the present invention are most generally formulated in any of the calories described in the following table (Example A_F) (the term "about" is used before each value). The total calories of nutrients. /. EXAMPLES Example B Example C Hydrophobic Compound 0-98 2-96 10-75 Protein 0-98 2-96 ~ 5-70 Fat 0-98 2-96 10^5~~" Example F Implementation Example D Example E Carbohydrate, ------- Bu 30-50 25-50 ~~ "25-50 5-30 Protein 15-35 10-30 Fat 35-55 1-20 _ T20 in a specific In the examples, liquid infant formulas (ie, ready-to-serve and concentrated liquids) include embodiments in which the protein component can comprise from about 7.5% to about 25% of the caloric content of the formulation; the carbohydrate component can comprise about 35 percent of the infant formula. % to about 50% of the total caloric content; and the fat component may constitute from about 30% to about 60% of the total caloric content of the infant formula. These ranges are provided by way of example only and are not intended to be limiting. Other suitable ranges (each term has the term "about"). 161215.doc •23· 201233329 Total nutrient calories % Example G Example 碳水化合物 Carbohydrate: 20-85 30-60 35-55 Fat: 5-70 20-60 25-50 Protein: 2-75 5- 50 7-40 When the nutritional product is a powdered preterm or term infant formula, the protein component is from about 5% to about 35%, including from about 8% to about 12%, by weight of the preterm or term infant formula. Included in an amount from about 1% to about 12%; the fat component is from about 1% to about 35%, including from about 25% to about 30% by weight of the preterm or term infant formula, and includes about 26 〇 / 〇 to about 28% of the amount; and the carbohydrate component is from about 30% to about 85%, including from about 45% to about 60% and including about 50% by weight of the preterm or term infant formula It is present in an amount of about 55%. For powdered human milk fortifiers, the protein component is from about 1% to about 55%, including from about 10% to about 50%, and including from about 10% to about 30%, by weight of the human milk fortifier. The amount is present; the fat component is present in an amount of from about 1% to about 30 °/〇, including from about 1 〇/q to about 25 %, and including from about 1% to about 20% by weight of the human milk fortifier And the carbohydrate component is present in an amount from about 15% to about 75%, including from about 15% to about 60%, and including from about 2% to about 50%, by weight of the human milk fortifier. The total amount or concentration of fats, carbohydrates, and proteins in the powdered nutritional products of the present invention can vary to a considerable extent depending on the selected product and the intended user's dietary or medical needs. Other suitable examples of macronutrient concentrations are listed below. In this context, total or concentration refers to all sources of fat, carbohydrate and protein in a powdered product. For powdered nutritional supplements, these totals or concentrations are most generally and preferably formulated within any of the specific ranges set forth in the table below (all values have "about" before). 161215.doc -24- 201233329

In addition to pre-digested fat, the nutritional products of the present invention may also contain other sources of fat (the total amount of fat referred to herein as the "fat component" or "fat system" of the nutritional product). Other fat sources suitable for use herein include any fat or fat source suitable for oral nutrition and compatible with the elements and characteristics of such products. Non-limiting examples of other fats or sources thereof suitable for use in the products described herein include coconut oil, fractionated coconut oil, soybean oil, corn oil, olive oil, safflower oil, high oleic safflower oil, oil Acid (emers〇l 6313 oleic acid), MCT oil (medium chain triglyceride), sunflower oil, high oleic sunflower oil, palm oil and palm oil, palm oil, fennel seed oil, aquatic animal oil , fish oil, fungal oil, algae oil, cottonseed oil and combinations thereof. In one embodiment, suitable fats or sources thereof include oils and oil combinations comprising long chain polyunsaturated fatty acids (LC-PUFA' preferably LC_PUFA having four or more double bonds). For example, certain non-limiting specific polyunsaturated acids that may be included include docosahexaenoic acid (DHA), arachidonic acid (ARA), eicosapentaenoic acid (EPA), and the like. . The pre-digested fats described herein are typically included in the nutritional product in combination with one, two, three, four or more other fat sources. In one embodiment 'single monoglyceride (ideally in the form of a single palm glycerol), a fatty acid (ideally in the form of a calcium salt), a high oleic oil and a coconut oil group 161215.doc -25· 201233329 Together to provide the fat component of the nutritional product. In this embodiment, the monoglyceride is from about 1% to about 4% by weight, including from about 10% to about 30%, including about 1%, about 15%, about 20% by weight of the fat component. , about 23% and about 25%) are present; the fatty acid is from about 1% to about 40° by weight of the fat component. (inclusive of from about 1% to about 3%, including about 10%, about 15%, about 2%, and about 25%); based on the weight of the fat component, 'high oleic acid oil is about 1 % to about 40% (including about 1% to about 30%, including about 10%, about 15%/〇, about 20%, about 25%, and about 30%); and the weight of the fat component The coconut oil is present in an amount from about 1% to about 40%, including from about 10% to about 30%, including about 10%, about 15%, about 17%, about 20%, and about 25%. In another embodiment, a fatty acid containing monoglyceride (ideally in the form of monopalmitate), a fatty acid component (ideally in the form of a salt), high oleic safflower oil, and coconut oil Combined to provide a fat component in the nutritional product. In this embodiment, the monoglyceride is from about 1% to about 40% by weight of the fat component, including from about 1% to about 30%, including about 10%, about 15%, about 20%, Approximately 23% and about 25%) are present; from about 1% to about 40% by weight of the fat component, including from about 1% to about 30%, including about 10%, about 15%, about The amount of 20% and about 25%) is present; the high oleic acid oil is about 1 〇/ by weight of the fat component. Up to about 4% (including about ι〇〇/0 to about 30%, including about 10% 'about 1 5%, about 20%, about 25%, and about 30%), and The oil is present in an amount of from about 1% to about 4% by weight, including from about 10% to about 30%, including about 10%, about 15%, about π%, about 20%, and about 25% by weight. In another embodiment, 'a fatty acid-containing monoglyceride (ideally 161215.doc -26·201233329 in the form of monopalmitic acid glyceride), a fatty acid component (ideally in the form of a calcium salt), high oil Saffron seed oil, coconut oil, DHA-containing oil, and ARA-containing oil are combined to provide a fat component in the nutritional product. In this embodiment, the monoglyceride is from about 1% to about 40% by weight of the fat component, including from about 10% to about 30%, including about 10%, about 15%, about 20%, about 23% and about 25%) are present; from about 1% to about 40% by weight of the fat component, including from about 10% to about 30%, including about 10%, about 15%, about 20% And about 25%) is present; the high oleic acid oil is about 1 by weight of the fat component. /. Up to about 40% (including about 10% to about 30%, including about 10%, about 15%, about 20%, about 25%, and about 30%); and by weight of the fat component, coconut oil It is present in an amount from about 1% to about 40%, including from about 10% to about 3%/0, including about 10%, about 15%, about 17%, about 20%, and about 25%. The DHA-containing oil is present in an amount from about 1% to about 丨〇% (including about $0/〇) by weight of the fat component and the ARA-containing oil is from about 1% to about 1% by weight of the fat component ( Including about 5%). In another embodiment, the fat component comprises about 38% by weight high oleic safflower oil, about 17% by weight coconut oil, and about 23% by weight monopalmitoyl glycerol. Ester, about 20% by weight fatty acid salt, about 0.5% by weight of DHA-containing oil and about 〇% by weight of ara oil. Protein / In addition to pre-digested fat, the nutritional product of the present invention may optionally contain a protein. Any protein source suitable for oral nutrition and compatible with the elements and ingredients of these products is suitable for use in combination with pre-digested fat. Non-limiting examples of a protein suitable for use in such nutraceuticals or sources thereof 161215.doc -27· 201233329 includes hydrolyzed, partially hydrolyzed or non-hydrolyzed protein or protein sources, which may be derived from any known or otherwise suitable Sources such as milk (eg casein, whey), animals (eg meat, fish), booties (eg rice, corn), plants (eg soybean) or combinations thereof. Non-limiting examples of such proteins include milk Protein-like isolates, milk protein concentrates as described herein, road protein isolates, extensively hydrolyzed casein, whey proteins, casein sodium or calcium salts, whole milk, partially or fully skimmed milk, soy protein Isolates, soy protein concentrates, and the like. Carbohydrates The nutritional products of the present invention may further comprise any carbohydrate suitable for oral nutrition and compatible with the elements and characteristics of such products, as appropriate.

Potassium, stevia) and combinations thereof. Other ingredients that exist as the case may be

An ingredient that is present as appropriate or otherwise suitable for use in a camping component. A variety of such products are known to be used in medical foods or other nutraceuticals, or in pharmaceutical compositions, and may also be used in the compositions herein, with the proviso that the components present in such conditions are orally safe and compatible. The ingredients of the selected product form are compatible. Non-limiting examples of such optional ingredients include preservatives, antioxidants, emulsifiers, buffers, fruit sugars, galactoses, probiotics, pharmaceutically actives, other nutrients as described herein. , colorants, flavoring agents, thickeners and stabilizers, emulsifiers, lubricants, and the like. The nutritional product may further comprise a sweetener, preferably comprising at least one sugar alcohol such as maltitol, erythritol, sorbitol, xylitol, mannitol, isomalt, and lactitol And preferably also includes at least one artificial or high potency sweetener such as acesulfame κ, aspartame, sucralose, saccharin, stevia and tagatose. Such sweeteners, especially in combination with sugar alcohols and artificial sweeteners, are particularly suitable for formulating liquid beverage embodiments of the present invention having a desired taste profile. These sweetener combinations are particularly effective for masking undesirable tastes sometimes associated with vegetable proteins added to liquid beverages. The concentration of sugar alcohol present in the nutritional product may be at least 0.01% by weight of the nutritional product, including from 1% to about 1%, and also including from about 1% to about 6%. Within the scope. The artificial sweetener concentration, as the case may be, may range from about 0.01% by weight of the nutritional product, including from about 5% to about 5%, and also from about 0.1% to about 1.0%. A flow or anti-caking agent can be included in the nutrient as described herein to delay the agglomeration or agglomeration of the powder over time and to produce a powder embodiment that readily flows out of its container. Any known flow or anti-caking agent known or otherwise suitable for use in nutritional powders or product forms is suitable for use herein, non-limiting examples of which are 161215.doc -29-201233329 including acid-filled three-fish, lycopene And combinations thereof. The concentration of the flow agent or anti-caking agent in the nutritional product varies depending on the product form, other selected ingredients, desired flow characteristics, etc., but is usually from about 1% to about 4 by weight of the nutritional product. 〇/. , including from about 0.5% to about 2%. Stabilizers can also be included in the nutritional product. Any stabilizer known or otherwise suitable for use in a nutraceutical is also suitable for use herein, some non-limiting examples of which include a mixture of vegetable gums and gums (such as Sanxian gum, based on the weight of the nutritional product, the stabilizer may From about 0% to about 5%, including from about 5% to about 3%, including from about 0.7% to about 1.5%. ^ The nutritional composition may further comprise any of a variety of other vitamins or related nutrients, Restricted examples include vitamin A, vitamin D, and only life

Prime, vitamin κ, serotonin, riboflavin, sputum. Polyol, vitamin I: carotenoid (such as β-caroline, zeaxanthin, lutein, sulphonin), acid, folic acid, pantothenic acid, biotin, vitamin C, gallbladder, inositol, Its salts and derivatives and combinations thereof. - Nutritional products may include any of a variety of other minerals, non-limiting examples of which include strontium, scale, lock, iron, zinc, turmeric, copper, sodium, potassium, s, and combinations thereof. In addition, in some implementations, the nutritional products can be free of horns and dishes. Method of Manufacture: The nutritional product of the invention can be prepared by any manufacturing technique known or otherwise available in the form of a solid or liquid product. : can be applied to the nutritional products described herein in any given product form (such as nutrition, etc.). I612I5.doc 201233329 Therefore, the nutritional product of the present invention can be used by any of various Prepared by known or otherwise effective products or manufacturing methods. For example, 'prepare at least three types of dips separately' in a suitable manufacturing process, including fat-packed protein (piF) slurries, carbohydrates/minerals (CH〇) _MIN) Slurry and water-packed protein (piwm material. PIF (4) is by heating and mixing oils (such as monoglyceride and/or fatty acids, oils containing yoghurt, fensyl oil, corn oil, etc.) And then, with continuous heating and stirring, an emulsifier (such as lecithin), a tamarind vitamin, and a part of total protein (for example, milk protein concentrate, etc.) are added to form. The CHO-Mmt system is stirred by heating. It is formed by adding the following substances to water: minerals (such as potassium citrate, dipotassium phosphate, sodium citrate, etc.), traces and ultra-trace minerals (TM/UTM premix) and/or thickening Agent or suspending agent (such as crystal Cellulose (avicel) gelatin (geHan), carrageenan. The resulting (:η〇_μιν slurry is kept under constant heating and stirring for 10 minutes, then other minerals (such as potassium carbonate, Magnesium carbonate, potassium iodide, etc.) and/or carbohydrates (for example, oligosaccharides, arachis, corn sugar (4)). If any residual protein f is present, the PIW slurry is formed by mixing with heating and stirring. In a particular embodiment of the invention, all or a portion of the pre-digested fat contained in the nutritional product may be added to the CH〇_MIN slurry, which contains less than 5% by weight of the CH0-MIN mass. a fat in the form of triglyceride vinegar. In this embodiment, at least 5% (by weight) of the total fat present in the nutrient is in the form of a digested fat and is added to the ch〇_min slurry. In certain embodiments, the nutritional product comprises at least 5% by weight, including at least 10% by weight, including at least 2% by weight (by weight J61215.doc 31 201233329), including At least 30% by weight, including at least 4% by weight, Including at least 50% by weight, including at least 6% by weight, including at least 70% by weight, including at least 8% by weight, including at least 90% by weight And including 1% by weight (by weight) of total pre-digested fat added to the (10) capture (four) feed. In a particular embodiment, before the pre-digested fat is added to the CH0.MIN stimuli or during manufacture During the CHO-Mm slurry, fat-soluble nutrients (such as mixed caroten (four) or vitamins A, D, EAK) are dissolved in pre-digested fat nails. In contrast to the agglomerates, by adding (four) to the CH0_MINMt (four), the final nutrition The stability of the composition can be improved. The resulting slurry is then blended with heating and the pH is adjusted to 6.6-7.0, after which the composition is subjected to high temperature short-term (htst) processing during which the composition is heat treated, emulsified and homogenized. And then make it chop. Add water-soluble vitamins and anti-spleen ‘ !! u Right, add the flavor to the pH: range' and add water to achieve the desired two. The composition is then aseptically packaged to form a sterile package. The emulsion may also be filled and subsequently liquid-type, left-handed to form a ready-to-eat or concentrate solution or it may be spray dried, dry blended and/or coalesced. The nutritive solids can be prepared by any known or otherwise suitable preparation and blending technology collection, effective nutrient powder. Spray-dried nutritional powder or dry blending For example, when the nutritional powder is a spray-drying drying step, it may similarly include known or spray drying techniques. Various spray drying methods and techniques are known to be used in the production of nutritional powders. 1612l5.doc •32-201233329 In the field of nutrition 'all spray-dried nutritional powders suitable for the manufacture of a spray-dried nutritional powder The method comprises forming and homogenizing an aqueous (tetra) or liquid comprising pre-digested fat and optionally protein f, carbohydrate and other sources of fat, and subsequently (d) drying the (iv) or liquid to produce a spray-dried nutritional powder. The method may further comprise the steps of spray drying, dry blending or otherwise adding additional nutrients to the haze dry nutritional powder (including any one or more of the ingredients described herein). Other suitable methods for preparing nutritional products are described, for example, in U.S. Patent No. 6,365,218 (B〇rschel et al.), U.S. Patent No. 6,589,576 (B., et al.), U.S. Patent No. 6,306,908 (Carlson et al), and U.S. Patent Application Serial No. In 〇3〇1187〇3 Al (Nguyen et al.), the description thereof is incorporated herein by reference. Methods of Use In accordance with the present invention and as further described below, the nutritional products described herein can be used for a variety of purposes including, for example, improving digestion, improving nutrient absorption, improving tolerance, reducing the incidence of necrotizing enterocolitis, and reducing abdominal pain. The incidence and the incidence of short bowel disease. Individuals (babies, toddlers, or children) who use the nutritional products described herein may actually have or suffer from the disease or condition (ie, may actually have digestive, nutrient absorption, and/or resistance or May have necrotizing enterocolitis, abdominal pain or short bowel disease, or may be prone to suffering from illness, may not have a family history of the disease, etc., and the disease or condition or presence in the general population This risk (also disease or condition, but due to the increased risk of certain strips than the disease). Regardless of whether the body actually has the disease or condition, or whether there is a risk of developing the disease or condition, or is prone to develop the disease or condition, the individual is classified as "needed" in this article. Help solve and fight the disease or condition. For example, an infant may actually have necrotizing enterocolitis due to premature birth or may be at risk of developing necrotizing enterocolitis (prone to necrotizing enterocolitis). Similarly, in another example, #儿 may actually have tolerance and/or digestive and/or nutrient absorption problems due to other diseases or conditions or family history with such problems' or may be present (easy to suffer) the risk of one or more of these conditions. Regardless of whether the individual actually has the disease or condition 'or whether there is only a risk of developing the disease or condition or is prone to develop the disease or condition', the invention includes assisting the individual with the nutritional products described herein. . Based on the above, certain method embodiments of the present invention are directed to determining a particular subgroup or subclass of an individual (ie, a subset of individuals that "need" to help resolve a particular disease or particular condition described herein or Subclass) 'Thus not all individuals may benefit from all of the method embodiments described herein, as for certain diseases or conditions, and not all individuals belong to a subgroup or subclass of individuals as described herein. W~6 I use a combination of other sources (4) to provide a source of fat for infants, toddlers and children to improve nutrient digestion and absorption. In particular, similar to = feeding the baby's digestion, because the fat source is in the intake - < 曰 之 之 被 被 被 被 , , , , , , , , , , , , , , , 被 被 被 被 被 被 被 被 , , , , , , , , , , (iv) 161215.doc -34- 201233329 Reduced nutrients that produce gas to reduce product tolerance. Thus, by using pre-digested fat sources (such as monoglycerides and/or fatty acids) in nutraceuticals, such as infant formulas, it is now possible to provide infants with breast milk substitutes or supplements that more closely mimic the benefits of breast milk. In addition to improved nutrient absorption as described above, it has been found that the use of pre-digested fats in nutrients with one or more water-insoluble hydrophobic mixtures (such as oil-soluble (fat-soluble) vitamins (vitamins A, D, £ and κ) When carotenoids (such as lutein, carotenoids, lycopene, etc.), glycolipids (neurolipids), sterols, and phytochemicals are added together, they also contribute to the formation of micelles. The formation of the microcells allows the insoluble hydrophobic compound to be dissolved in the digest, which is a step of intestinal villus absorption. In addition, the pre-digested fat will be used to re-synthesize triglyceride to form chylomicrons. The chylomicrons will be water-insoluble and hydrophobic. The compound is carried into the lymph, wherein the circulation delivers the insoluble hydrophobic compound to the target organ and/or tissue to produce the desired physiological effect. In addition to the benefits discussed above, it has been found that nutrients comprising pre-digested fat stimulate the duodenum Cholecystokinin (CCK) is produced, which stimulates the production of pancreatic lipase. This produces further digestion of nutrients and reduces upper gastrointestinal tract. Shrinkage, which allows more time for absorption. Therefore, the use of pre-digested fat in nutrient σ reduces the total amount of nutrients that enter the colon and are fermented and produce gas and swell. Therefore, use in nutrients Pre-digested fat can be modified to improve tolerance by improving nutrient digestion and absorption (with less flatulence). This is especially important for infants because tolerance may be a problem in some infants. 161215.doc -35 - 201233329 In addition to stimulating CCK production, 'pre-digested fat has also been found to induce secretion of intestinal growth hormone (glycoside-like peptide-2 'GLP-2). GLP-2 enhances intestinal maturation in infants, which allows digestion and Better absorption of nutrients. It has been further discovered that a nutrient containing pre-digested fat as described herein can be used to provide a source of nutrition for infants, young children or children, which can reduce necrotizing enterocolitis (NEC), abdominal pain and/or The incidence of short bowel disease. In addition, in contrast to the protein in the fat slurry, by adding at least a portion of the pre-digested fat to the carbohydrate-mineral slurry (or in some In the examples of the method of making nutrients for all methods of pre-digesting fat, the resulting stability of the nutritional product (usually in the form of a nutritional emulsion) can be improved. EXAMPLES The following examples illustrate specific embodiments of the nutritional products of the present invention and/or The examples are given for illustrative purposes only and are not to be construed as limiting the invention, as many variations may be present without departing from the spirit and scope of the invention. % by weight based on the total weight of the composition. Examples of compositions are storage stability nutritional products prepared according to the manufacturing methods described herein such that, unless otherwise stated, each exemplary product includes aseptically processed examples. And examples of sterilized autoclave encapsulation. The nutrient liquid example is packaged in a 240 ml plastic container and is 1-25 after compounding/packaging. . An oil-in-water aqueous emulsion that maintains physical stability within a period of ... at storage temperatures within the range. Examples 1-4 161215.doc • 36 - 201233329 Examples 1-4 illustrate lactose-free infant nutritional emulsions of the present invention, the ingredients of which are listed in the following table. Unless otherwise stated, all ingredient amounts are listed in kilograms per 1000 kg batch of product. Ingredient Example 1 Example 2 Example 3 Example 4 Water sufficient amount sufficient amount sufficient amount of maltodextrin 53 43.3 50 60 sucrose 16.5 25 19.2 16.38 Milk protein isolate 15.65 15.65 15.65 15.65 Corn oil 12 12 12 12 High oleic acid safflower seeds Oil 10 10 10 10 Monopalmitic acid glycerol S 10 9 8 7 c10-c24 fatty acid mother salt 6.0 7 8 9 coconut oil 2 2 2 2 fungal oil 0.3 0.3 0.3 0.3 egg fat 0.1 0.1 0.1 0.1 dipotassium hydrogen phosphate 0.96 0.96 0.96 0.96 Potassium chloride 0.3 0.3 0.3 0.3 Ascorbic acid 0.235 0.235 0.235 0.235 Angular vegetable gum 0.150 0.150 0.150 0.150 Potassium hydroxide 0.136 0.136 0.136 0.136 TM/UTM premix 0.1684 0.1684 0.1684 0.1684 Vitamin A, D, E premix 0.0758 0.0758 0.0758 0.0758 Water-soluble vitamin premix 0.0728 0.0728 0.0728 0.0728 Potassium sulphate 0.00022 0.00022 0.00022 0.00022 Chromium chloride 0.000217 0.000217 0.000217 0.000217 Example f; -8 Examples 5-8 illustrate the lactose-based nutritional emulsion of the present invention, the ingredients of which are listed below In the table. Unless otherwise stated, all ingredient quantities are listed in kg per 1000 kg batch of product. Ingredient Example 5 Example 6 Example 7 Example 8 Water sufficient amount sufficient amount sufficient lactose 58 66 71 63 non-fat dry milk 25 10 0 16 whey protein concentrate 6.4 13 18 10.5 high oleic acid safflower oil 14 14 14 14 161215.doc -37- 201233329 Coconut oil 6.2 6.2 6.2 6.2 Monopalmitate 10 8 6 4 C10-C24 fatty acid 5.5 7.5 9.5 11.5 Fruit oligosaccharide / galactooligosaccharide 9 9 9 9 Fungal oil 0.3 0.3 0.3 0.3 Phosphoric acid Dihydrogen potassium 0.96 0.96 0.96 0.96 Hydrogen hydroxide in the bow 0.78 1.07 1.36 1.64 Calcium oxide 0.3 0.3 0.3 0.3 Ascorbic acid 0.235 0.235 0.235 0.235 Carrageenan 0.150 0.150 0.150 0.150 Potassium hydroxide 0.136 0.136 0.136 0.136 TM/UTM premix 0.1684 0.1684 0.1684 0.1684 Premix of vitamin A, D, E 0.0758 0.0758 0.0758 0.0758 Water-soluble vitamin premix 0.0728 0.0728 0.0728 0.0728 Mothing oblique 0.00022 0.00022 0.00022 0.00022 Calcined chromium 0.000217 0.000217 0.000217 0.000217 Examples 9-12 Examples 9-12 illustrate the invention Soy-based infant nutritional emulsions, the ingredients of which are listed in the table below. Unless otherwise stated, all ingredient amounts are listed in kilograms per 1000 kg batch of product. Ingredient Example 9 Example 10 Example 11 Example 12 Water sufficient amount sufficient amount sufficient amount of corn syrup solids 53 43.3 50 60 sucrose 16.5 25 19.2 16.38 soy protein isolate 19.5 19.5 19.5 19.5 corn oil 12 12 12 12 high oleic acid safflower seed oil 10 10 10 10 Monopalmitate 10 9 8 7 c10-c24 fatty acid 6.0 7 8.0 9 Fungal oil 0.3 0.3 0.3 0.3 L-cystamic acid 2.3 2.3 2.3 2.3 L-tyrosine 1.1 1.1 1.1 1.1 Hydrogen peroxide 0.09 1.0 1.1 1.2 L-tryptophan 0.66 0.66 0.66 0.66 Dipotassium hydrogen phosphate 0.96 0.96 0.96 0.96 Calcium oxide 0.3 0.3 0.3 0.3 Ascorbic acid 0.235 0.235 0.235 0.235 Angular vegetable 0.150 0.150 0.0 0.0 161215.doc •38· 201233329 | Potassium 0.136 0.136 0.136 0.136 TM/UTM premix 0.1684 0.1684 0.1684 0.1684 Vitamin A, D, E premix 0.0758 0.0758 0.0758 0.0758 Water soluble vitamin premix 0.0728 0.0728 0.0728 0.0728 Potassium iodide 0.00022 0.00022 0.00022 0.00022 Example 13-16 Example 13- 16 illustrates a hydrolyzed protein-based infant nutritional emulsion of the present invention, the ingredients of which are listed in the following table. Unless otherwise stated, all ingredients are listed in kilograms per 1000 kg batch. Ingredient Example 13 Example 14 Example 15 Example 16 Water sufficient amount sufficient amount sufficient sucrose 42 42 42 42 starch 21.8 21.8 21.8 21.8 hydrolyzed protein 22.2 22.2 22.2 22.2 high oleic acid safflower oil 13.7 13.7 13.7 13.7 MCT oil 6 6 6 6 Monopalmitin 10 9 8 7 c10-c24 fatty acid 11 9.5 8 6.5 Coconut oil 5 7.5 9 11.5 Fungal oil 0.3 0.3 0.3 0.3 Oxide mother 1.6 1.29 1.1 0.93 L-methionine 0.3 0.3 0.3 0.3 Dipotassium hydrogen phosphate 0.96 0.96 0.96 0.96 Calcium Oxide 0.3 0.3 0.3 0.3 Ascorbic Acid 0.235 0.235 0.235 0.235 Carrageenan 0.0 0.0 0.150 0.150 Potassium Hydroxide 0.136 0.136 0.136 0.136 TM/UTM Premix 0.1684 0.1684 0.1684 0.1684 Vitamin A, D, E Premix 0.0758 0.0758 0.0758 0.0758 Water-soluble vitamin premix 0.0728 0.0728 0.0728 0.0728 Potassium iodide 0.00022 0.00022 0.00022 0.00022 Example 17 In this example, the absorption of c1()-c24 fatty acid calcium salt and related bioavailability in rats was assessed. 161215.doc 39- 201233329 Thirty rats were randomly assigned to one of three diets containing different protein and fat (diet 1, diet 2 and diet 3). Diets 1-3 are the same as those used in AOAC Method 906.48. The difference is that Diet 1_3 has a higher fat content and contains maltodextrin as a carbohydrate source. Diet 1 contains 1% by weight of protein for acid path protein and 23.6 wt% of fat can be used as containing 3% by weight of coconut oil '30 wt% soybean oil and 40 wt% high oleic safflower seed oil (HOSO) Oil blend. The nutritional forms of diets 2 and 3 are the same as those of diet i, except that proteins, fats, carbohydrates, and minerals are mixed 'homogeneized and spray dried. Diet 3 differs from diet 2 only in that it uses high oleic acid safflower oil fatty acid calcium salt for RH〇s eucalyptus oil and potassium phosphate instead of dicalcium phosphate to make the overall nutrition and mineral form of diet 2 diet 3. the same. HOSO fatty acid calcium salt provides 1% of dietary calcium. The rats were fed diet 1, diet 2 or diet 3 for a period of 4 weeks. Feed conversion (grams of weight gain/kg of feed intake) and protein efficiency ratio (kg of weight gain/gram of protein ingested) (pER) were calculated using feed/protein intake and weight gain at the end of the feeding trial. If (4) bad absorption, the caloric value of HOSO fatty acid 33 salt (ie, calories per kilogram) is significantly lower than the caloric value of HOSO, then it is expected that rats of diet 3 will increase their body weight or take more feed to maintain their Growth, both of which result in lower feed conversion and PER. The results shown in the table below show that rats in diet 3 have the same feed conversion or PER as the control group, indicating that the caloric value of the H〇s〇 fatty acid salt is not different from HOSO oil. Therefore, it is shown that the shame-fat (four) salt has a high birth rate of 16I2l5.doc -40. 201233329 protein effect Bibby feed conversion diet 1 (control group 1) 2.83 +/- 0.28* 0.29 +/- 0.03 diet 2 (control group 2) 3.16 +/-0.17 0.31 +/-0.02 Diet 3 (fatty acid salt) 3.32+/-0.27 0.37 +/- 0.03 *standard deviation (n=10) Example 18 In this example 'analysis of 10 days of pigs versus soybeans Absorption of fatty acid salts. Sixteen suckling pigs were randomly divided into two groups and individually housed in metabolic cages and trained to obtain a nutritional emulsion from the pot within 30 minutes. After one week of training with a commercially available ready-to-eat hydrolyzed protein-based formulation, the pigs were fed a commercially available hydrolyzed protein-based formula powder (control) containing phosphoric acid #5 and carbonic acid as an approximate source or containing soy fatty acid calcium. Salt is used as a calcium source emulsion (experimental emulsion). For the control and experimental emulsions, the protein source and content, fat content and mineral form were the same. However, the experimental emulsion contained soybean oil (iv) in place of soybean oil in the control group and contained hydroxide as part of the mom mineral system to neutralize the soybean fatty acid. The potassium phosphate content of the experimental emulsion was adjusted to match the phosphorus content of the control. Soy fatty acid calcium provides 100 〇/〇 in the experimental emulsion. After two weeks of feeding, the apparent fat and calcium digestibility were calculated based on the following formula: Apparent fat digestibility = ((fat intake - fecal fat) / fat intake) * 丨 00 Apparent digestibility = ((calcium intake) - fecal calcium) / calcium intake) * 100 dry matter digestibility = ((dry (four) intake - fecal dry matter) / dry matter intake) * 1 〇〇 experimental emulsion reduced feed conversion (weight / feed intake) and reduced fat 'The dry matter digestibility will show the poor absorption of soy fatty acid salt in the experimental emulsion' and thus shows that for the experimental emulsion, the calorific value of calcium and the bioavailability of 16U15.doc -41 · 201233329 are lower than the control group. The feed conversion, fat digestibility and dry matter digestibility of the experimental emulsions in the table below were significantly different from those of the control group, which showed that the soybean fat lysate of the experimental emulsion for the nascent pig was highly absorbed and bioavailable. In addition, the digestibility data shown below shows that the experimental emulsion has a more bioavailability than the soy fatty acid salt of the experimental emulsion, which is about (i.e., tricalcium phosphate and calcium carbonate). Control group experimental emulsion _ apparent fat digestibility 97.6+/- 1.0 97.6+/- 1.4 : standard deviation (n=10) 0.82+/-0.14* 0.80+/-0.15 feed-(Zhao weight increase grams / feed ( Dry matter) grams) Apparent calcium digestibility Apparent dry matter digestibility 81.8 +/- 7.2 97.8 +/- 0.7 91.3 +/- 3.3 98.0 +/- 1 . Example 19 In this example, the fatty acid salt was analyzed. Emulsifying properties. Cut with 5 〇〇mi water using a tabletop 咼 shear mixer 1 8 § 13 0°F containing glyceryl monopalmitate (5 parts by weight of soybean oil and 43 〇 mg Ca (tricalcium phosphate form) To prepare a first emulsion (control emulsion). A second emulsion (calcium fatty acid emulsion) containing the same amount of calcium and fat (12 g of soybean oil plus 6 g of soy fatty acid) as a control emulsion was prepared by: (1) Dispersing the soybean fatty acid oil solution in water at a temperature of about 130 °F; (2) adding 430 mg of Ca in the form of calcium chloride; (3) adjusting the positive value of the solution to about 7.0 ' using KOH. (4) Shearing with a tabletop high shear mixture; Kun character. 161215.doc •42· 201233329 The control emulsion and the fatty acid calcium emulsion were allowed to stand for three weeks to analyze the emulsion separation. After one night, the 'control emulsion was A visible phase separation containing a milky layer appeared on top of the emulsion (see Figure 1A). In contrast, the fatty acid #5 emulsion showed only slight speculation at the top of the emulsion after three weeks of storage (but not beta). About the soap layer' while the emulsion remains in one phase. In fat There is no visible mother sediment at the bottom of the emulsion (see Figure 1Β). These results show that the fatty acid calcium salt is an effective emulsifier and can provide a calcium source for the nutritional emulsion that does not substantially settle from the solution. This makes the emulsion product have improved stability. Sexuality and longer shelf life. Example 20 In this example, the fat uptake and maternal absorption of 1 independent test formulation and control formulation were measured for 1 day old pig. 1) contains palm oil essential oil in the fat system 'The second test formulation (Formulation 2) contains pre-digested fat in the fat system' and the control formulation (Formulation 3) contains low palmitic acid in the fat system The fat system components of the two formulations are listed in the following table: % (g) - Γ - - 碉 ligand 1 (palm oil essential oil) Formulation 2 (pre-digested fat formula) 3 (Contrast formulation containing low-pumped palm acid oil) Coconut oil " ~3Z2 0 84.1 oleic acid safflower oil fatty acid - () 2.8 * 〇---- 108 ~ 56 ^ 9 - 111.9 0 Δ Ό A · ,丄'Ί •Λ-ΚΑ m Τ〇3 ------- 3.03 3.03 |dha^ '~~~~ _ early palmitic acid glycerin S 1.52 "7:----- 1.52 1.52 0 65.4 0 9P exhausted this day ·, 1 small *- ""** "*" 1.12 1.12 1.12 % exclusive/yield soybean oil '^ J22?7~- 0 0 J7T 0 83.8 --1 161215.doc -43· 201233329 Prepare three kinds of nutrients and mineral types with almost the same Formulation. The fatty acid form of Formulations 1 and 2 mimics the fatty acid form of the breast milk. Formulation 2 contains calcium hydroxide (amount sufficient to sequester all free fatty acids) as a source which reacts with the soy fatty acid to form an insoluble fatty acid calcium salt. This reaction eliminates the bitter taste and throat burning sensation produced by free fatty acids. In addition, the amount of potassium phosphate in Formulation 2 was raised to match the dish content in Formulations 1 and 3. The calcium salt used in Formulations 1 and 3 is calcium phosphate. Allow 60 10-day large pigs (plus or minus two days) to be randomly assigned to receive the formulation! , Formulation 2 or Formulation 3 » The pigs were individually housed in metabolic cages and fed five times a day for three weeks after training and adaptation for 4 days. Fecal material from day 2 to day 18 was collected and analyzed for calcium absorption and fat absorption. Calcium absorption is calculated by dividing the amount of calcium in the fecal material by the amount of calcium in the diet and multiplying by 1 〇〇. The fat absorption is calculated by dividing the amount of fat in the fecal material by the amount of fat in the diet and multiplying by 1 〇〇. The results are shown in the table below. Fat Absorption (%) Calcium Absorption (%) Formulation 1 (Brown Oil) 92.3 ± 3.9 88.9 ± 4_7 Formulation 2 (pre-digested fat) 98'2 ± 0.7 93, 1 ± 2.4 Formulation 3 (Control: Low Palmitic Fat System) 98.0 ± 1.4 90.7 ±3_5 As shown in the results above, the use of a pre-digested fat system allows the infant formula to mimic the fatty acid profile of the breast without the appearance of calcium and fat as experienced in the palm oil essential oil system. Adverse effects of absorption. Formulation 2 (pre-digested fat formulation) has a fat and calcium absorption rate that is at least as good as the fat and calcium absorption rate of the low palmitic acid formulation. These findings indicate that soy fatty acid I bow salts are highly bioavailable in newborn pigs. Example 21 I6I215.doc -44- 201233329 In this example, the post-prandial increase in CCK production (AUC) and enterokin production (AUC) of the pig of Example 20 was evaluated. In the conclusion of the fat and calcium absorption analysis described in Example 20, pigs administered Formulation 2 (pre-digested fat formulation) or Formulation 3 (including low palmitic acid control formulation) were fasted for 12 hours. And fasting blood is drawn to separate the serum. The pigs were allowed to recover for two hours and then 250 mL of Formulation 2 or Formulation 3 was administered. Postprandial blood samples were taken at 30 and 60 minutes after feeding and CCK and enterin were tested. The post-prandial increase in CCK (area under the curve) and enterin (AUC) was calculated. The results are shown in the table below. Formulation 2 (pre-digested fat formulation) (pg/mL^min) Formulation 3 (control: low palmitic acid formulation) (pg/mL*min) Post-prandial increase in CCK secretion (area under the curve) 1935 ± 1464 1046 ±754 Enterin AUC (post-prandial increase) 483 ± 253 839 ± 403 The data in the above table shows that replacing pre-digested fat (monopalmitin plus soy fatty acid) with triglyceride stimulates postprandial CCK Secretion, which has been shown to stimulate pancreatic digestive enzyme secretion, enhance gallbladder contraction, and delay oral to cecal delivery. Thus, formulations with pre-digested fat stimulate more secretion of digestible enzymes and slow GI delivery to allow for more nutrient digestion and absorption. Therefore, formulations containing pre-digested fat can improve formulation tolerance, as undigested nutrients can cause excessive colonic fermentation to cause flatulence, diarrhea, and stomach. In addition, the data in the above table shows pre-digested fat (monopalmitic acid). Substituting diglycerides with glycerides plus soy fatty acids reduces postprandial intestinal motility. Infants with abdominal pain have been shown to have a lower post-prandial CCK content, but 161215.doc •45-201233329 has a mild postprandial enterin content. This imbalance between postprandial gut hormones causes the baby to contract GI, which causes abdominal pain. The data in the above table shows that the inclusion of pre-digested fat can increase the CCK content of the baby after a meal, but reduce the intestinal motility content, thereby reducing the hormone imbalance to relieve GI contraction, abdominal pain and abdominal pain. Example 22 In this example, pigs of Example 20 were used to study the effect of various fat systems on the contents of chylomicron triglyceride palmitate and Sn-2 palmitic acid. A sample was also taken from each pig after 1 hour of meal and plasma was separated, frozen in liquid nitrogen and stored in a freezer at -80 °C. Total plasma lipids were extracted using Folch solvent. The triglyceride was separated by thin layer chromatography. The table below shows the blood polytriglyceride palmitic acid and Sn-2 palmitic acid in Formulation 1 (palm oil blend formulation) and Formulation 2 (pre-digested fat formulation). The table also shows chylomicron triglycerides and Sn-2 palmitic acid in pigs fed the two formulations. Formulation 1 (Brown Oil 4 Show) Pigs' Triglyceride Formulation 2 for Feeding Formulation 1 : (Pre-digested Fat) Rice Feed Formulation 2 Pig's Plasma Triglyceride Milk for Human Infant It is a post-triglyceride triglyceride Sn-2 triglyceride Sn-2 triglyceride Sn-2 triglyceride Sn-2 triglyceride vinegar Sn-2 palmitic acid content (%) 23.3 5.8 18.3 10.6 21.4 5.2 18.5 14.4 25 25.5 As shown in the table above, the plasma triglyceride and Sn-2 palmitic acid levels of pigs fed the pre-digested fat formula were significantly higher than those of the palm oil formula. The ratio of plasma triglyceride palmitic acid/Sn-2 palmitic acid of Formulation 1 and Formulation 2 was about 1.7 and 1.3, respectively, and the ratio of known breast-fed infants was about 1 _1. Therefore, this data shows that the pre-digested fat formulation mimics breast milk better than the palm oil-based fat § week. 16l215.doc -46- 201233329 Example 23 In the 5 hai example, the pig of Example 20 was used to study the effect of various fat systems on the blood lutein content. Plasma from a 1 hour postprandial jk fluid sample from each pig was extracted using a solvent of chloroform and methanol (ratio 2:1). The solvent was removed and the resulting lipids were pooled and analyzed for lutein using conventional methods. The following table shows the lutein content of pigs fed with Formulation 1 (palm oily formulation), Formulation 2 (pre-digested fat formulation), and Formulation 3 (low palmitic acid formulation), per mg of lipid Lutein is called a number. Formulation 1: (Peach Palm Oil) Formulation 2: (Pre-digested fat) Formulation 3: (Low palmitic acid) Lutein contains N/A* 0.765 pg 0.539 μβ * Formulation 1 lutein content Too low to measure. As indicated in the above table, pigs fed a formulation containing pre-digested fat had increased lutein absorption compared to pigs fed a formulation containing palm olein or low palmitic acid. Example 24 In this example, Formulation 2 (pre-digested fat formulation) and Formulation 3 (low palmitic acid formulation) of Example 20 were used to study the effect of various fat systems on the lutein content of the cells. Formulation 2 and Formulation 3 were reconstituted with water (133 g of powdered formulation per 1.0 L of water), and the pH of the reconstituted formulation was adjusted to 4.5 by the addition of HC1. The reconstituted formulation was digested for 1 hour at room temperature by adding i.00 ml USP pepsin (56 mg/ml) to 40 ml of the reconstituted formulation. After pepsin digestion 161215.doc -47· 201233329 Adjust the pH of the reconstituted formulation to 7.0, and then add 28 mg USP trypsin/protease, 28 mg USP trypsin fat to the pepsin-digested formulation. A mixture of enzyme and 1 mg of bile extract. The formulation was further digested for 2 hours at room temperature and centrifuged (31,0 〇〇§ at 20° (:3 hours). The digested formulation formed an oil/creamt clot, an aqueous phase, and a sedimentation layer. The aqueous phase was extracted for lutein analysis of the micelles which served as a carrier during the absorption of lutein in the aqueous lumen. The following table shows the content of lutein in the microcapsule per kg of the digested formulation. 2: (pre-digested fat) Digested Formulation 3 : (Low palmitic acid) Microcytophyllin (pg) 0.598 μβ 0.246 pg As shown in the table above, the micro-discovery contained in the digested formulation containing pre-digested fat The amount of lutein was more than twice the amount of lutein found in the digested formulation containing low palmitic acid, thus showing that the use of pre-digested fat increased lutein absorption. Example 25 In this example, Analysis of the ability of pre-digested fat to reduce the incidence of soft stools. 30 weaned rats were fed a hydrolyzed protein-based infant formula (containing MCT oil as a 30 wt% fat source) for a four-day acclimation period. At the end, the rats were randomly divided into two groups. Promising control formulation (low palmitic acid powder infant formula) or test formulation (infant formula containing pre-digested fat). The control formulation is the same as the nutrient form of the test formulation. The rats are given free access to feed and water. For five days, the amount and weight of the ingested feed were recorded daily. 161215.doc -48 * 201233329 Although there was no significant difference in feed intake or weight gain between the two groups, there was a significant difference in the firmness of the sputum. During the last two days, the rat's stool firmness score was scored using the 〇5 point system. The score was based on the severity and firmness of the stool from the sticky gentleman to the bottom of the cage. The 〇 score value indicates normal stool and 5 scores. Watery diarrhea was indicated. As shown in Figure 2, rats fed a control formulation (containing MCT oil) produced a thin stool compared to the test test formulation (containing pre-digested monthly fat). In this example 'analyze the ability of pre-digested fat to reduce the incidence of necrotizing enterocolitis (NEC). Premature pigs (92% of pregnancy) delivered via caesarean section are immediately transferred to an oxygenated incubator (37) And a vascular catheter was placed in the umbilical artery. The pigs were injected three times (4, 6 and 7 mL/kg body weight) through the vascular catheter during the first 24 hours. Total parenteral nutrition (TPN) was provided at a rate of 6 mL/kg for 24 hours. The pigs were then randomized to receive at a rate of 5 mL/kg per hour via an orgastric tube. Control formulation or pDF formulation. In addition to the fat system therein, the control formulation is the same as the pDF formulation. In particular, the fat system in the formulation contains vegetable oil and the fat system in the pDF formulation contains 3〇 Wt 〇 / 0 monopalmitin, 2 〇 ^ % soybean fatty acid, 26 wt% high oleic safflower oil, 14 wt% coconut oil and 1 〇 wt% glyceryl tributyrate. Both the control formulation and the pDF formulation contained 1 g protein, 47 g fat, and 5 g g corn syrup per liter of the formulation. The pigs were euthanized and subjected to autopsy for 36 hours after enteral feeding to assess the severity of NEC lesions using the I61215.doc -49 - 201233329 1-5 scoring system, with a score of 1 indicating no signs of NEC. The results are shown in the table below. Block 1 Block 2 Control Formulation (n=5) PDF Formulation (n=3) Control Formulation (n=5) PDF Formulation (π=3) Early NEC Death 2 0 3 1 Detection at Autopsy NEC 2 1 0 0 Total NEC 4 1 3 1 As shown in the table above, 5 of the 10 pigs fed the control formulation (50%) died of NEC before the end of the enteral feeding period, but fed the PDF blending Only 1 out of 6 pigs (16.7%) died of NEC before the end of the enteral feeding period. In addition, 7 of the 10 pigs fed the control formulation (70%) had NEC measured before the end of the enteral feeding period, while only 2 of the 6 pigs fed the PDF formulation (33) %) NEC was determined before the end of the enteral feeding period. It can therefore be concluded that the incidence of NEC can be reduced by replacing the vegetable oil fat system with a fat system containing pre-digested fat. BRIEF DESCRIPTION OF THE DRAWINGS Figures 1A and 1B show graphical representations of a control emulsion and an experimental emulsion prepared as in Example 19. Figure 2 is a graph showing the effect of diet on fecal firmness. 161215.doc •50·

Claims (1)

201233329 VII. Patent application scope: 1 · A nutrient fat system containing at least 1% by weight of a fatty acid-containing monoglyceride, wherein at least 70 of the fatty acids in the monoglyceride are in position . 2. The fat system of claim 1 wherein the monoglycerides are monopalmitoyl glycerol. 3. The fat system of claim 1, wherein at least 80% of the fatty acids are in the Sn-Ι position. 4. The fat system of claim 1 which comprises the fat system comprising at least i 5 wt of a fatty acid containing monoglyceride. 5. The fat system of claim 1, wherein the fat system comprises from about 12% to about 45% by weight of a monoglyceride containing a fatty acid. 6. The fat system of claim 1, wherein the fat system comprises from about 5 wt% to about 25 wt% of a monoglyceride containing a fatty acid. 7. The fat system of claim 1, wherein the fatty acid-containing monoglyceride is obtained by enzymatic hydrolysis of lard, tallow or a combination thereof. 8. An infant formula fat system comprising at least 1% by weight of a fatty acid-containing monoglyceride, wherein at least 70% of the fatty acids in the monoglyceride are in the Sn] position. 9. The fat system of claim 8, wherein the monoglyceride is glyceryl monopalmitate. 10. The fat system of claim 8 wherein at least 80% of the fatty acids are in the Sn-1 position. 11. The fat system of claim 8, wherein the fat system comprises at least b 161215.doc 201233329 wt% of a monoglyceride containing a fatty acid. 12. The fat system of claim 8, wherein the fat system comprises from about 12 wt% to about 45 wt% of the fatty acid-containing monoglyceride from t. 13. The fat system of claim 8, wherein the stagnation system comprises from about 15 wt〇/〇 to about 25 wt% of the fatty acid-containing monoglyceride. 14. The fat system of claim 8, wherein the T-fusin contains a fatty acid monosaccharide::: obtained by enzymatic hydrolysis of lard, tallow or a combination thereof. The fat system of about 85% to about 亀 of the fat I is in the Sn-Ι position. 161215.doc